http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107849026-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42e94091a4fc81b8d0237117707cc7ee
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4353
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-20
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4353
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04
filingDate 2016-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c56dfbca1664b105c1ccf74253c177e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21fd7fbb79f28d9512cc7fed659169f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44d5fbed5d59bbd75d292098c9070428
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c96afbf62b5b4741d3dccc8f23084ace
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a28e4230fa1667a4b6c44fb85af3f8aa
publicationDate 2018-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-107849026-A
titleOfInvention Factor XIA macrocycle inhibitors carrying an alkyl or cycloalkyl P2, moiety
abstract The present invention provides a compound of formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein all variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. The invention also relates to pharmaceutical compositions comprising these compounds and methods of using these compositions to treat thromboembolic and/or inflammatory disorders.
priorityDate 2015-07-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104507924-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102753555-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467451725
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466035728
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467779014
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID409221893
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID468148746
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID164165762
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467395068
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID465142493
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466909903
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID163551361
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID468223739
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467231228
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID126508657

Total number of triples: 45.